Reduction for Generic Competition. If a Third Party sells a product that contains the same Compound, Derivative or Additional Licensed Compound as found in the Licensed Product sold in a country in the Territory, then VIA’s royalty obligations to Roche under Sections 4.1 and 4.3 with respect to sales in such country shall be reduced as follows: ***.
Appears in 4 contracts
Samples: Research, Development and Commercialization Agreement, Research and Development (Madrigal Pharmaceuticals, Inc.), Research, Development and Commercialization Agreement (Via Pharmaceuticals, Inc.)
